FATE News and Press, Fate Therapeutics Inc. From 01/05/23

Summary Shares have fallen by over 80% during the past 12 months. iPSC-derived NK cell programs sport advantages such as streamlined manufacturing, optimization and convenient administration. Solid tumor efforts and vast IP are two aspects of the story I feel are under-appreciated. ...

Fate Therapeutics ( NASDAQ: FATE ) is trading ~6% lower after Oppenheimer downgraded rating to Perform from Outperform. The company last week reached a 52-week low after announcing preclinical data with its partner GT Biopharma ( GTBP ) to highlight the potential...

SAN DIEGO, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, presented preclinical data of several novel strategies designed to enable a...

Fate Therapeutics ( NASDAQ: FATE ) reached a 52-week low on Monday after announcing preclinical data with its partner GT Biopharma ( NASDAQ: GTBP ) to highlight the potential of a new therapeutic approach to treat acute myeloid leukemia (AML). The data, as presented at the ong...

Presentation shows the therapeutic potential of combining iPSC-derived CAR NK cells and NK cell engagers to overcome the clinical heterogeneity of AML BRISBANE, CALIFORNIA, Dec. 12, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP) today announce...

Interim Phase 1 Data of FT576 BCMA-targeted Product Candidate Show Clinical Activity in Initial Single-dose Escalation Cohorts as Monotherapy and in Combination with Daratumumab Preclinical Data under Janssen Collaboration with FT555 GPRC5D-targeted Product Candidate Demonstrate Robust ...

FT819 Off-the-Shelf CAR T-cell Product Candidate Derived from Clonal Engineered Master iPSC Line with Novel CD19-specific 1XX CAR Integrated into TRAC Locus Interim Phase 1 Dose-escalation Data Indicate Favorable Safety Profile with Complete Responses in Heavily Pre-treated Patients wit...

Summary Fate is an industry leader in small molecules-induced pluripotency. However, after 15 years of R&D, it only has phase 1 studies. The company has potential, but it is taking a long time to get there. For further details see: ...

Summary Fate Therapeutics was one of my favorite investments, however, I made the haunting mistake of closing the position only to see the ticker nearly triple. This time will be different. FATE has lost roughly 60% over the past twelve months. I believe the ticker is trading near...

Summary NKTX came out with strong data in heavily pretreated AML patients in April. Data was at least as good as Fate's data, which is valued nearly 4x higher. Lack of near-term catalysts and a secondary is keeping the stock down. Nkarta ( NKTX ) is a company tha...